Akèy › Kansè ovè › North Carolina
Etid klinik pou Kansè ovè nan North Carolina
44 etid pou Kansè ovè ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Oct 5, 2026 · NCT06995898Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- University of North Carolina-Hillsborough Campus, Hillsborough
- Wake Forest University Health Sciences, Winston-Salem
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT07001748Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- Southeastern Medical Oncology Center-Clinton, Clinton
- ak 9 plis
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 5, 2026 · NCT05564377A Study of PHST001 in Advanced Solid Tumors
- Duke Cancer Institute, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT06840886A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Carolina Cancer Research Center, Wilson
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07059884Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07360314A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of North Carolina Medical Center /ID# 275307, Chapel Hill
- Atrium Health Levine Cancer Institute /ID# 274557, Charlotte
- East Carolina University - Brody School of Medicine /ID# 275770, Greenville
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0259 - Duke Cancer Center, Durham
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05128825DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Duke Cancer Institute, Durham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Duke University Medical Center, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- FirstHealth of the Carolinas- Speciality Center /ID# 278636, Pinehurst
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07059845A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Duke Cancer Center ( Site 0012), Durham
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 17, 2026 · NCT07318558Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Levine Cancer Center, Charlotte
- Novant Presbyterian Hospital, Charlotte
- East Carolina University, Greenville
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT07214779ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- Duke, Durham
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 14, 2026 · NCT04575935A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Charlotte
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT05123482A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- FirstHealth Cancer Center ( Site 0079), Pinehurst
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT06824467Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Levine Cancer Institute, Charlotte
- East Carolina University, Greenville
- Atrium Health Wake Forest Baptist, Comprehensive Cancer Center, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Aug 26, 2026 · NCT05281471A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Atrium Health - Wake Forest, Charlotte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07470853A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Mission Hospital, Asheville
- Hope Women's Cancer Centers-Asheville, Asheville
- Duke Cancer Center Cary, Cary
- ak 7 plis
Ap rekrite
Laj 35 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT04251052A Study of DM002 in Patients With Advanced Solid Tumors
- Carolina BioOncology Institute, LLC, Huntersville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06751329Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- Duke Women's Cancer Care Raleigh, Raleigh
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07749586A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem
Ap rekriteFaz 2
Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797The Better, Harder, Faster, Stronger Study
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Ap rekriteEtid obsèvasyon
Laj 55 ak plis · Fanm · Mizajou Jul 15, 2026 · NCT07220512CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
- Duke University, Durham
Ap rekriteFaz 1/2
Laj 18 a 75 · Fanm · Mizajou Jul 13, 2026 · NCT07322094Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- UNC Hospital, Chapel Hill
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 2, 2026 · NCT06819007Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- GSK Investigational Site, Charlotte
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 24, 2026 · NCT04641247Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Carolina BioOncology Institute, Huntersville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT06993844Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
- Lineberger Comprehensive Cancer Center, Chapel Hill
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou May 19, 2026 · NCT06305299Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Duke Cancer Center, Durham
- Duke Women's Cancer Care Raleigh, Raleigh
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Apr 16, 2026 · NCT05659381REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
- Duke Cancer Center, Durham
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Apr 13, 2026 · NCT06710548A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
- Site 0259, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Apr 7, 2026 · NCT04516447TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
- Duke University Hospital, Durham
Ap rekrite
Laj 25 a 50 · Fanm · Mizajou Apr 6, 2026 · NCT04294927Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Levine Cancer Institute (LCI)- Atrium Health, Charlotte
- Duke Cancer Center/ DUMC, Durham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT05735080A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Duke Cancer Institute, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT06778863Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.